CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease. |
|
|
| Terminated | 4 | 3 | US | Ocrelizumab, Placebo | Yale University, Genentech, Inc. | Radiologically Isolated Syndrome, Multiple Sclerosis | 06/23 | 06/23 | | |